November 23, 2023

Linius Technologies (ASX:LNU), a pioneer in cloud-based video solutions, is set to make a significant impact on the US college sports market with its latest venture. Linius has announced a groundbreaking agreement to provide its sports solution, Whizzard, to the Peach Belt Conference (PBC), marking its entry into the lucrative US collegiate sports market. Under […]

Chimeric Therapeutics (ASX:CHM), an Australian company specialising in cell therapy, has reported significant in vitro findings for its chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy, CHM 1301. These preclinical results highlight the therapy’s notable efficacy against ovarian and pancreatic cancers, suggesting potential advancements in cancer treatment. CHM 1301 represents a fusion of Chimeric’s

Sequoia Financial Group Limited (ASX:SEQ) Managing Director and CEO Garry Crole and Chairman John Larsen present at the company’s 2023 AGM. Chairman’s Speech Good morning, ladies, and gentlemen. My name is John Larsen, Chairman of Sequoia Financial Group Ltd and it is my pleasure to welcome you to our 2023 Annual General Meeting. I welcome

The S&P/ASX 200 is 0.52 per cent lower at 7,036.40. Aus. energy stocks are trading in the red due to the postponement of an OPEC meeting to later next week, dampening hopes of the cartel tightening its supplies.  The SPI futures are pointing to a fall of 37 points. Best and worst performers The best-performing

To register for Friday’s webinar click here. Chimeric Therapeutics (ASX:CHM) announced positive preclinical data for CHM 1301, the Company’s off-the-shelf cell therapy. The results show up to 300% enhanced cell killing demonstrated compared to first generation NK cells and there is evidence of expansion into two new solid tumours – pancreatic cancer and ovarian cancer.